Advancing Toward HIV-1 Vaccine Efficacy through the Intersections of Immune Correlates.
about
Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus MacaquesProgress in HIV-1 vaccine development.Modeling HIV vaccine trials of the future.Lessons learned from human HIV vaccine trials.Model-robust inference for continuous threshold regression models.V1V2-specific complement activating serum IgG as a correlate of reduced HIV-1 infection risk in RV144.Oral Delivery of a Novel Recombinant Streptococcus mitis Vector Elicits Robust Vaccine Antigen-Specific Oral Mucosal and Systemic Antibody Responses and T Cell Tolerance.Head-to-Head Comparison of Poxvirus NYVAC and ALVAC Vectors Expressing Identical HIV-1 Clade C Immunogens in Prime-Boost Combination with Env Protein in Nonhuman PrimatesBreakthrough of SIV strain smE660 challenge in SIV strain mac239-vaccinated rhesus macaques despite potent autologous neutralizing antibody responses.HIV-1-Specific Antibody Response and Function after DNA Prime and Recombinant Adenovirus 5 Boost HIV Vaccine in HIV-Infected Subjects.Antibody-Mediated Internalization of Infectious HIV-1 Virions Differs among Antibody Isotypes and SubclassesChanges in Circulating B Cell Subsets Associated with Aging and Acute SIV Infection in Rhesus MacaquesBreakthrough Virus Neutralization Resistance as a Correlate of Protection in a Nonhuman Primate Heterologous Simian Immunodeficiency Virus Vaccine Challenge Study.HLA class II genes modulate vaccine-induced antibody responses to affect HIV-1 acquisition.Tissue memory B cell repertoire analysis after ALVAC/AIDSVAX B/E gp120 immunization of rhesus macaques.Immunization with an SIV-based IDLV Expressing HIV-1 Env 1086 Clade C Elicits Durable Humoral and Cellular Responses in Rhesus Macaques.Selection of HIV vaccine candidates for concurrent testing in an efficacy trial.Complex immune correlates of protection in HIV-1 vaccine efficacy trials.Immunogenicity of a novel Clade B HIV-1 vaccine combination: Results of phase 1 randomized placebo controlled trial of an HIV-1 GM-CSF-expressing DNA prime with a modified vaccinia Ankara vaccine boost in healthy HIV-1 uninfected adults.HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-SpeciSieve analysis of breakthrough HIV-1 sequences in HVTN 505 identifies vaccine pressure targeting the CD4 binding site of Env-gp120.HIV-1 Envelope Glycoproteins from Diverse Clades Differentiate Antibody Responses and Durability among Vaccinees.Modification of the Association Between T-Cell Immune Responses and Human Immunodeficiency Virus Type 1 Infection Risk by Vaccine-Induced Antibody Responses in the HVTN 505 Trial.
P2860
Q27318508-CBE570C2-1F9B-4D75-8D2D-EB7CB5649612Q27693849-76B42C08-8435-46A2-B367-8B2784C40CA3Q30393307-44570082-CCBC-4ED5-8B80-5CA52D599140Q33557844-C0B95F9D-60CC-4C8F-9C88-532259328D43Q33699928-88107347-D7C9-44C8-B63D-61412C9C73B7Q33874253-0EE12C61-4430-45D4-AC2E-6D4EE810AA80Q35855579-D5C7B6BF-9FAC-456A-9EBD-B57D2D98C677Q35914311-EB7F5AD5-E199-481C-9FCB-6C940845A2B1Q36008380-E68E893B-7524-42EE-8EC0-156E5C5B9309Q36097352-8C193C88-26CB-4F8F-B187-98D0AE9751B5Q36118373-5E63E3B8-A5A1-470F-8969-E6A570381560Q36251503-88CE0BBA-D84D-44BE-BAA8-BE6E1AFAF80AQ36334371-C103EF5A-7DA7-4EB8-A25C-793E895C837EQ37013490-BEF9FC73-704A-43E1-861C-B15998D64B62Q37469197-70BBFE47-90F9-4298-9DD6-A90967758F17Q37499531-B2D5A2BA-E76B-4B9E-8B86-DAC5CB08C2B1Q38716886-76FE1D87-CF3E-4F30-8092-BCCDCF789C23Q39108779-0E803303-3F64-4009-AB9F-CD085285DDCBQ40114912-80268DD9-E2B9-43C5-BC93-B4D0CE613DA7Q40339467-4F02D944-1AA8-49C5-8232-CE48C9EDF5EEQ46633111-5112BCFE-8A56-4961-89F7-16818D0F0714Q47547483-AE2D4ED0-9A47-4595-AF96-1B10B6252D9BQ50084407-E32D0953-D274-4E5A-84B4-D4CC82DEE101
P2860
Advancing Toward HIV-1 Vaccine Efficacy through the Intersections of Immune Correlates.
description
2014 nî lūn-bûn
@nan
2014 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մարտին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Advancing Toward HIV-1 Vaccine Efficacy through the Intersections of Immune Correlates.
@ast
Advancing Toward HIV-1 Vaccine Efficacy through the Intersections of Immune Correlates.
@en
type
label
Advancing Toward HIV-1 Vaccine Efficacy through the Intersections of Immune Correlates.
@ast
Advancing Toward HIV-1 Vaccine Efficacy through the Intersections of Immune Correlates.
@en
prefLabel
Advancing Toward HIV-1 Vaccine Efficacy through the Intersections of Immune Correlates.
@ast
Advancing Toward HIV-1 Vaccine Efficacy through the Intersections of Immune Correlates.
@en
P2860
P356
P1433
P1476
Advancing Toward HIV-1 Vaccine Efficacy through the Intersections of Immune Correlates.
@en
P2093
Georgia D Tomaras
P2860
P356
10.3390/VACCINES2010015
P577
2014-03-01T00:00:00Z